E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Equipment and Supplies [E07] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary Aim 1 Pilot Study: Assess dose-response relationship to define dose for the main study Primary Aim 1 Main Study: Evaluate the ability of dOFM to assess bioequivalence (BE) between different diclofenac products |
|
E.2.2 | Secondary objectives of the trial |
Secondary Aim 1 Pilot Study: Test for absence of systemic cross-talk (systemic redistribution) Secondary Aim 2 Pilot Study: Test for absence of lateral diffusion (cross-talk between adjacent treatment sites) Secondary Aim 3 Pilot Study: Compare non-equivalent test product with reference product
Secondary Aim 1 Main Study: Monitor systemic cross-talk (systemic redistribution) To monitor if topically applied diclofenac is absorbed into the systemic circulation and is redistributed back into the skin, blood samples and dermal ISF samples from a distant untreated site on the arm will be taken, to assess its diclofenac concentrations.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Healthy, adult volunteers of age 18 to 65 years (both inclusive). 2. Males or non-pregnant, non-breast feeding females using adequate contraceptive methods or abstinence. 3. Able to read, understand and sign the written informed consent form. 4. Willing to follow the protocol requirements and comply with protocol restrictions.
|
|
E.4 | Principal exclusion criteria |
1. Social habits a. Smoker who is not willing to refrain from smoking during the in-house visit. b. History of drug and/or alcohol abuse within one year of start of study as judged by the investigator. 2. Medications: Use of any medications other than hormonal contraceptive, hormone replacement therapy or routine vitamins within the 7 days or 5 half-life periods whichever is longer prior to the initial dose of study medication. 3. Diseases: Presence of any clinically relevant acute or chronic disease, which in the investigator´s opinion might jeopardise subject`s safety, evaluation of results or compliance with the protocol. 4. Any reason, which in the opinion of the investigator, would prevent the subject from safely participating in the study. 5. Any abnormalities found during physical examination or vital signs, unless deemed not clinically significant by the investigator. 6. Clinically significant abnormal laboratory evaluation results, as deemed by the investigator. 7. Clinically significant abnormal 12-lead ECG at screening, as deemed by the investigator. 8. Positive results to the test for hepatitis B antigen or hepatitis C antibodies. 9. Positive HIV test. 10. Positive alcohol breath test. 11. Blood donation within 30 days or significant loss of blood or plasma (more than 550 ml) within 90 days prior to screening. 12. Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication. 13. Known hypersensitivity to diclofenac or any components of the drugs. 14. Tattoos or broken and/or damaged skin and/or scarring at the application areas. 15. Active skin diseases like psoriasis or atopic dermatitis, as judged by the investigator. 16. Subjects prone to keloid or hypertrophic scar formation or any known wound healing disorder. 17. Recent and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc.), as judged by the investigator. 18. Not willing to avoid excessive sun exposure, steam baths, sauna, swimming and other strenuous activities for 14 days after Visit 2 to ensure good tissue regeneration. 19. Not willing to refrain from shaving the planned treatment sites or using skin care products on the planned treatment sites for at least 5 days prior to start of Visit 2. 20. Pronounced hairiness on the planned treatment sites that may negatively affect BE testing. 21. Known allergy/hypersensitivity to any of the materials/supplies used during the study. 22. Presence of needle phobia. 23. Not enough space on the thighs for the dOFM probe set-up ( |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Pilot Study: Skin penetration data: Dermal diclofenac concentrations in ISF samples Area under the diclofenac concentration-time curves (AUC) in the ISF samples Maximum observed diclofenac concentration (Cmax) in the ISF samples in the ISF samples
Main Study: Skin penetration data: o Diclofenac concentrations in ISF samples o Area under the diclofenac concentration-time curves (AUC) o Maximum observed diclofenac concentration (Cmax) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Pilot Study: Skin penetration data: o Diclofenac concentrations in ISF samples o Diclofenac concentrations in blood samples o Area under the diclofenac concentration-time curves (AUC) o Maximum observed diclofenac concentration (Cmax)
Main Study: Secondary Endpoints The following additional endpoints were selected to enable the evaluation of the Secondary Aims (see section 2):
• Systemic diclofenac concentration o Concentrations in the blood samples o Area under the diclofenac concentration-time curves (AUC) in the blood samples o Maximum observed diclofenac concentration (Cmax) in the blood samples • Dermal PK profile of the untreated test sites: o Dermal concentrations in ISF samples o Area under the diclofenac concentration-time curves (AUC) in the ISF samples o Maximum observed diclofenac concentration (Cmax) in the ISF samples
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Yes |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | Yes |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |